BioCentury
ARTICLE | Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

June 14, 2019 11:50 PM UTC

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors
Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met the primary endpoint of improving progression-free survival (PFS) in an interim analysis of the Phase III SANET-ep China trial for low or intermediate grade advanced extra-pancreatic neuroendocrine tumors.

BeiGene reports 80.8% ORR for zanubrutinib
BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said its Btk inhibitor zanubrutinib (BGB-3111) led to an 80.8% overall response rate and a 54% major response rate in the ASPEN Phase III study to treat Waldenström's macroglobulinemia in patients harboring the MYD88WT genotype associated with poor prognosis and low response rates. One of 17 evaluable patients achieved a complete response. BeiGene presented the data at the European Hematology Association (EHA) meeting in Amsterdam...